Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment

Dow Jones12-03

By Connor Hart

Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer.

The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression.

CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers.

Corbus said it expects to report the first data from the study during the first quarter of 2025.

The FDA's fast-track designation facilitates the development and expedites the review of drugs intended to treat conditions that demonstrate the potential to fill an unmet medical need.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 03, 2024 07:20 ET (12:20 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488365919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488365919","market":"fut","top_or_hot":-1,"title":"Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<p>\n  Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. \n</p>\n<p>\n  The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression. \n</p>\n<p>\n  CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers. \n</p>\n<p>\n  Corbus said it expects to report the first data from the study during the first quarter of 2025. \n</p>\n<p>\n  The FDA's fast-track designation facilitates the development and expedites the review of drugs intended to treat conditions that demonstrate the potential to fill an unmet medical need. \n</p>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:20 ET (12:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n  Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. \n\n\n  The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488365919","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488365919","pubTimestamp":1733228400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer.The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression.CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers.Corbus said it expects to report the first data from the study during the first quarter of 2025.The FDA's fast-track designation facilitates the development and expedites the review of drugs intended to treat conditions that demonstrate the potential to fill an unmet medical need.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","CRBP":"Corbus Pharmaceuticals Holdings, Inc.","BK4104":"贸易公司与经销商","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","FAST":"快扣","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC"},"translate_title":"Corbus Pharmaceuticals获得FDA宫颈癌治疗快速通道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBP":1,"FAST":1},"content_text":"By Connor Hart \n\n\n  Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. \n\n\n  The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression. \n\n\n  CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers. \n\n\n  Corbus said it expects to report the first data from the study during the first quarter of 2025. \n\n\n  The FDA's fast-track designation facilitates the development and expedites the review of drugs intended to treat conditions that demonstrate the potential to fill an unmet medical need. \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 07:20 ET (12:20 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488365919"}